If you are:
FDB Only When Necessary: AVOID CHRONIC HIGH DOSE
FDB Only When Necessary: NOT ABSORBED UNLIKELY TO CAUSE TERATOGENIC AND NON-TERATOGENIC EFFECTS
FDB Contraindicated or Not Recommended: FDA C BEFORE 30WKS;PREMATURE CLOSURE OF DUCTUS ARTERIOSUS;EARLY MISCARRIAGE RISK
No Known Risk: POOR GI ABSORPTION
Precaution: INSUFFICIENT DATA AVAILABLE; LOW LEVELS FOUND IN BREASTMILK
No Known Risk: EXCRETED IN ANIMAL STUDIES;POOR GI ABSORPTION
No Known Risk: INSUFFICIENT DATA AVAILABLE; DRUG DOES NOT APPEAR TO BE ABSORBED BY GI TRACT
An adult over 60:
management or monitoring precaution: May cause diarrhea. Caution in renal impairment.
management or monitoring precaution: Gastrointestinal-Risk for ulceration or serious GI bleed; highest with history of PUD or GI bleed. Renal-Risk for exacerbation of CKD. Cardiovascular-May exacerbate pre-existing hypertension or CHF. Risk of cardiovascular thrombotic events, including MI and stroke. This risk may occur early in treatment and increases with duration of use. Risk for reinfarction with minimal NSAID use post-MI. Contraindicated with CABG. Hepatic-Elevated hepatic transaminases may occur with chronic use.
management or monitoring precaution: May cause constipation. Overuse may affect bone mineralization.
Giving Flanax oral to a child under 12:
management or monitoring precaution: Rare risk of osteomalacia with high dose therapy.
management or monitoring precaution: Safety and efficacy not established in children age less than 2 years.